Net sales:
KSEK 22 (down from KSEK 338)
Quarterly loss:
KSEK -6,798 (improved from KSEK -7,435)
Operating expenses:
KSEK -7,967 (down from KSEK -8,964)
Earnings per share:
SEK -0.01 (improved from SEK -0.02)
Cash at end:
KSEK 25,923
Appointed Torsten Malmström as Director CMC & Supply
DMC recommended continued recruitment in Tumorad-01 trial at current dose
Post-quarter:
DMC confirmed maximum tolerated dose met at 15 MBq/kg, additional patients recommended
Observed tumor uptake in head and neck cancer patient
Abstract accepted for ANZSNM meeting May 15-17, 2026